RS61773B1 - Kristalni oblici antagonista androgenog receptora, postupak njihove pripreme i upotrebe - Google Patents
Kristalni oblici antagonista androgenog receptora, postupak njihove pripreme i upotrebeInfo
- Publication number
- RS61773B1 RS61773B1 RS20210521A RSP20210521A RS61773B1 RS 61773 B1 RS61773 B1 RS 61773B1 RS 20210521 A RS20210521 A RS 20210521A RS P20210521 A RSP20210521 A RS P20210521A RS 61773 B1 RS61773 B1 RS 61773B1
- Authority
- RS
- Serbia
- Prior art keywords
- preparation
- receptor antagonist
- androgen receptor
- crystal forms
- crystal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610737732 | 2016-08-26 | ||
| CN201610871736 | 2016-09-30 | ||
| CN201610876685 | 2016-10-08 | ||
| PCT/CN2017/099036 WO2018036558A1 (zh) | 2016-08-26 | 2017-08-25 | 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途 |
| EP17842980.9A EP3495352B1 (en) | 2016-08-26 | 2017-08-25 | Crystal forms of an androgen receptor antagonist, preparation method and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61773B1 true RS61773B1 (sr) | 2021-05-31 |
Family
ID=61246439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210521A RS61773B1 (sr) | 2016-08-26 | 2017-08-25 | Kristalni oblici antagonista androgenog receptora, postupak njihove pripreme i upotrebe |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10815221B2 (sr) |
| EP (1) | EP3495352B1 (sr) |
| JP (1) | JP6716023B2 (sr) |
| CN (1) | CN109641851B (sr) |
| CY (1) | CY1124083T1 (sr) |
| DK (1) | DK3495352T3 (sr) |
| ES (1) | ES2869882T3 (sr) |
| HR (1) | HRP20210667T1 (sr) |
| HU (1) | HUE053958T2 (sr) |
| LT (1) | LT3495352T (sr) |
| PL (1) | PL3495352T3 (sr) |
| PT (1) | PT3495352T (sr) |
| RS (1) | RS61773B1 (sr) |
| SI (1) | SI3495352T1 (sr) |
| WO (1) | WO2018036558A1 (sr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018162793A1 (en) * | 2017-03-07 | 2018-09-13 | Orion Corporation | Manufacture of a crystalline pharmaceutical product |
| CN116396220A (zh) | 2017-08-09 | 2023-07-07 | 杭州领业医药科技有限公司 | Odm-201晶型及其制备方法和药物组合物 |
| US20210087175A1 (en) * | 2018-02-27 | 2021-03-25 | Sandoz Ag | Crystalline Form II of Darolutamide |
| JP2022505033A (ja) * | 2018-10-18 | 2022-01-14 | ジェムフィアー セラピューティクス インコーポレイテッド | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 |
| WO2022036782A1 (zh) * | 2020-08-18 | 2022-02-24 | 拜耳消费者护理股份有限公司 | 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途 |
| MX2024009980A (es) | 2022-02-28 | 2024-08-26 | Quim Sintetica S A | Forma cristalina de darolutamida. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR078793A1 (es) * | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| MX360611B (es) * | 2011-04-21 | 2018-11-09 | Orion Corp | Carboxamidas que modulan el receptor de andrógeno. |
| PT3250554T (pt) * | 2015-01-30 | 2022-06-02 | Orion Corp | Um derivado de carboxamida e os seus diastereómeros na forma cristalina estável |
| CN116396220A (zh) | 2017-08-09 | 2023-07-07 | 杭州领业医药科技有限公司 | Odm-201晶型及其制备方法和药物组合物 |
-
2017
- 2017-08-25 WO PCT/CN2017/099036 patent/WO2018036558A1/zh unknown
- 2017-08-25 PT PT178429809T patent/PT3495352T/pt unknown
- 2017-08-25 US US16/328,249 patent/US10815221B2/en active Active
- 2017-08-25 EP EP17842980.9A patent/EP3495352B1/en active Active
- 2017-08-25 PL PL17842980T patent/PL3495352T3/pl unknown
- 2017-08-25 JP JP2019511530A patent/JP6716023B2/ja active Active
- 2017-08-25 SI SI201730734T patent/SI3495352T1/sl unknown
- 2017-08-25 DK DK17842980.9T patent/DK3495352T3/da active
- 2017-08-25 LT LTEP17842980.9T patent/LT3495352T/lt unknown
- 2017-08-25 CN CN201780048143.1A patent/CN109641851B/zh active Active
- 2017-08-25 HU HUE17842980A patent/HUE053958T2/hu unknown
- 2017-08-25 RS RS20210521A patent/RS61773B1/sr unknown
- 2017-08-25 ES ES17842980T patent/ES2869882T3/es active Active
-
2021
- 2021-04-27 HR HRP20210667TT patent/HRP20210667T1/hr unknown
- 2021-04-27 CY CY20211100367T patent/CY1124083T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3495352B1 (en) | 2021-01-27 |
| ES2869882T3 (es) | 2021-10-26 |
| CN109641851A (zh) | 2019-04-16 |
| JP6716023B2 (ja) | 2020-07-01 |
| JP2019526570A (ja) | 2019-09-19 |
| DK3495352T3 (da) | 2021-05-03 |
| HRP20210667T1 (hr) | 2021-05-28 |
| WO2018036558A1 (zh) | 2018-03-01 |
| HUE053958T2 (hu) | 2021-08-30 |
| EP3495352A1 (en) | 2019-06-12 |
| PL3495352T3 (pl) | 2021-08-02 |
| US20200239450A1 (en) | 2020-07-30 |
| PT3495352T (pt) | 2021-05-03 |
| CN109641851B (zh) | 2022-09-02 |
| CY1124083T1 (el) | 2022-03-24 |
| EP3495352A4 (en) | 2019-06-12 |
| US10815221B2 (en) | 2020-10-27 |
| LT3495352T (lt) | 2021-06-10 |
| SI3495352T1 (sl) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1247204A1 (zh) | 用於雄激素受體的靶向降解的化合物和方法 | |
| HUE053958T2 (hu) | Androgén receptor antagonista kristályos formái, elõállítási eljárása és alkalmazása | |
| HK1250710A1 (zh) | 用於製備雄激素受體拮抗劑及其中間體的方法 | |
| EP3094346A4 (en) | Vista antagonist and methods of use | |
| IL284005A (en) | Glucocorticoid receptor inhibitors | |
| EP3313396A4 (en) | G-PROTEIN-COUPLED RECEPTOR CINASE INHIBITORS AND METHOD OF USE THEREOF | |
| HUE055891T2 (hu) | A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja | |
| PL3216791T3 (pl) | Substancja polimorficzna chlorowodorku jonkenafilu, sposób jej wytwarzania oraz jej kompozycja i zastosowanie | |
| HK1250163A1 (zh) | 作為5-氧代-ete受體拮抗劑的吲哚類似物及其使用方法 | |
| GB201500638D0 (en) | Scaffold fitting means and method of use thereof | |
| IL284081A (en) | Somatostatin receptor antagonistic compounds and methods of using them | |
| PT3348546T (pt) | Forma cristalina de um inibidor de recetor de androgénio e o seu método de preparação | |
| EP3336088A4 (en) | CRYSTALLINE FORM OF THE OREXIN RECEPTOR ANTAGONIST COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | |
| EP3674294C0 (en) | N-FORMYL VORTIOXETINE, METHOD FOR PREPARING IT AND SOLID PREPARATION OF VORTIOXETINE |